22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
On March 31, 2020, the National Labor Relations Board (NLRB) announced that it had finalized a serie...
Read More >
New Jersey Governor Phil Murphy signed into law on July 2, 2019 the Jake Honig Compassionate Use Med...
Read More >
A federal appeals court just resurrected the salary history ban that will now prevent Philadelphia e...
Read More >
With the New Year comes changes in many state and federal wage and hour laws. Do you operate in a st...
Read More >
Your company has just made its largest acquisition ever and your CEO says they want you to have a co...
Read More >
On April 24, 2020, Washington Governor, Jay Inslee, signed an addendum to Proclamation 20-25 that al...
Read More >